Evidence map›Paper›PMID 29272282›Full record

ArticlePloS one2017

Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.

Beata Przybyla, Anne Pinomäki, Jari Petäjä, Lotta Joutsi-Korhonen, Karin Strandberg, Andreas Hillarp, Ann-Kristin Öhlin, Tapani Ruutu, Liisa Volin, Riitta Lassila

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Graft-Versus-Host Disease Sustains Coagulation Activity for two Years After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Beata PrzybylaCoagulation Disorders Unit, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1014-668X
Anne PinomäkiStem Cell Transplantation Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Jari PetäjäDepartment of Paediatrics, Helsinki University Hospital, Helsinki, Finland.
Lotta Joutsi-KorhonenHematology and Clinical Chemistry and HUSLAB Laboratory Services, Helsinki University Hospital, Helsinki, Finland.
Karin StrandbergDepartment of Clinical Chemistry, Lund University, Lund University Hospital, Lund, Sweden.
Andreas HillarpDepartment of Clinical Chemistry, Lund University, Lund University Hospital, Lund, Sweden.
Ann-Kristin ÖhlinDepartment of Clinical Chemistry, Lund University, Lund University Hospital, Lund, Sweden.
Tapani RuutuStem Cell Transplantation Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Liisa VolinStem Cell Transplantation Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Riitta LassilaCoagulation Disorders Unit, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Helsinki University Hospital · FILund University · SEUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllogeneic stem cell transplantation (SCT) enhances coagulation via endothelial perturbation and inflammation. Role of natural anticoagulants in interactions between coagulation and inflammation as well as in acute graft-versus-host disease (GVHD) are not well known. The purpose of this study was to define changes in natural anticoagulants over time in association with GVHD. PATIENTS AND

methodsThis prospective study included 30 patients who received grafts from siblings (n = 19) or unrelated donors (n = 11). Eight patients developed GVHD. Standard clinical assays were applied to measure natural anticoagulants, represented by protein C (PC), antithrombin (AT), protein S (PS), complex of activated PC with its inhibitor (APC-PCI) and by markers of endothelial activation: Factor VIII coagulant activity (FVIII:C) and soluble thrombomodulin (s-TM) at 6-8 time points over three months.

resultsOverall, PC, AT and FVIII:C increased in parallel after engraftment. Significant correlations between PC and FVIII:C (r = 0.64-0.82, p<0.001) and between PC and AT (r = 0.62-0.81, p<0.05) were observed at each time point. Patients with GVHD had 21% lower PC during conditioning therapy and 55% lower APC-PCI early after transplantation, as well as 37% higher values of s-TM after engraftment. The GVHD group had also increases of PC (24%), FVIII: C (28%) and AT (16%) three months after transplantation.

conclusionThe coordinated activation of natural anticoagulants in our longitudinal study indicates the sustained ability of adaptation to endothelial and inflammatory activation during allogenic SCT treatment. The suboptimal control of coagulation by natural anticoagulants at early stage of SCT may contribute to onset of GVHD.

Indexed as

Hematopoietic Stem Cell TransplantationAcute DiseaseAnticoagulantsFemaleGraft vs Host DiseaseHumansLongitudinal StudiesMaleProspective StudiesTransplantation, HomologousAnticoagulants

Identifiers

PMID29272282
PMCPMC5741247
OpenAlexW2780565677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.